4//SEC Filing
DUGAN RICHARD W 4
Accession 0001209191-20-032896
CIK 0001347178other
Filed
May 28, 8:00 PM ET
Accepted
May 29, 4:10 PM ET
Size
9.2 KB
Accession
0001209191-20-032896
Insider Transaction Report
Form 4
DUGAN RICHARD W
Director
Transactions
- Exercise/Conversion
Nonstatutory Stock Option (Right to Buy)
2020-05-28−15,000→ 0 totalExercise: $7.38Exp: 2020-06-02→ Common Stock (15,000 underlying) - Sale
Common Stock
2020-05-28$11.04/sh−10,129$111,806→ 40,641 total - Exercise/Conversion
Common Stock
2020-05-28$7.38/sh+15,000$110,700→ 50,770 total
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire June 2, 2020 as reflected in this Form 4.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.99 to $11.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vested in 12 equal monthly installments beginning on July 3, 2010.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001263499
Filing Metadata
- Form type
- 4
- Filed
- May 28, 8:00 PM ET
- Accepted
- May 29, 4:10 PM ET
- Size
- 9.2 KB